AmgenAMGN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$226B

Price

$443.84

Today

+1.0%

Return YTD

+34.2%

Return 1Y

+48.5%

P/E

25.8

P/S

5.9

P/B

19.3

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

BiotechOncologyObesity exposureObesity

In the value chain

Products & services

Oncology & haematology
Immunology
Obesity pipeline (MariTide)

Competitors

AbbVie
Novo Nordisk (obesity)
Eli Lilly

Risks

Patent expirations
Clinical risk in pipeline

Supply chain

Supplies →

CencoraCOR

← Suppliers

DanaherDHR West Pharmaceutical ServicesWST IQVIA HoldingsIQV Thermo Fisher ScientificTMO

Full supply chain for AMGN →

Same segment: Biotech & innovation

Gilead SciencesGILD Vertex PharmaceuticalsVRTX RegeneronREGN BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY United TherapeuticsUTHR

Compare AMGN

AMGN vs GILD AMGN vs VRTX AMGN vs REGN AMGN vs BIIB AMGN vs ALNY AMGN vs MRNA

See where Amgen sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →